
Sign up to save your podcasts
Or


Former FDA Investigator Explains Why Your Risk Assessment Is All Green | Peter Baker
When management treats a red risk as a compliance failure, how honestly can a team assess its processes?
Former FDA investigator Peter Baker returns to Let’s Combinate: Drugs + Devices for a conversation with Subhi Saadeh about data integrity, quality risk management, and the problems hidden inside an all-green risk assessment.
Peter challenges the familiar justification that “we’ve never had a deviation” means something is unlikely to happen. He explains his approach to evaluating vulnerability in processes involving people, asking whether a failure can happen, whether it would be detected, and whether it can be prevented.
We also discuss ALCOA+, the patient impact of incomplete or inaccurate data, differences between pharmaceutical and medical device risk management, and how data governance connects process design, operation, and monitoring.
CHAPTERS
00:00 Peter Baker returns
01:06 How FDA inspections led him to data integrity
01:54 Trial injections and pretesting samples
03:18 ALCOA+ and the impact on patients
05:13 Part 11, Annex 11, and FDA’s regulatory approach
08:35 Why data integrity problems persist
11:44 Where are the red risks?
12:49 Human behavior and the limits of probability
13:41 Assessing vulnerability
14:46 ICH Q9 and ISO 14971
16:43 FMEA, detectability, and probability of harm
18:34 Can it happen, be detected, or be prevented?
20:12 Lessons from combination products
21:51 Connecting deviations and complaints to the risk file
23:24 Why companies need data governance
25:03 Design, operation, and monitoring
26:10 Resources for learning more
27:36 Connect with Peter Baker
ABOUT PETER BAKER
Peter is the Founder and President of Live Oak Quality Assurance, specializing in data integrity, data governance, and quality risk management. He spent 11 years with the FDA, including seven years in its overseas offices in India, China, and Chile. Named FDA Investigator of the Year in 2013, he conducted more than 100 foreign drug inspections. His investigative work is featured in Katherine Eban’s bestselling book Bottle of Lies.
ABOUT SUBHI SAADEH
Subhi is the Founder and Principal of Combinate, a consulting practice specializing in combination product quality, drug delivery systems, and the intersection of pharmaceutical and medical device requirements. His background includes engineering, manufacturing, and quality leadership experience at Baxter, Pfizer, and Gilead Sciences. He hosts Let’s Combinate: Drugs + Devices, exploring the people, processes, and decisions behind product quality.
Learn more about Peter’s work at [Live Oak Quality Assurance](https://www.liveoakqa.com).
Pharma outsourcing, CDMO selection, and contract manufacturing are changing as biotech funding, manufacturing capacity, and sponsor expectations shift. Raman Sehgal joins Subhi Saadeh to discuss the CDMO market in 2026, what makes a reliable manufacturing partner, and how AI in drug discovery could shape demand for outsourced development and manufacturing.
Recorded at CDMO Live Americas, this conversation examines what happens when a supplier’s capabilities look right on paper, but the experience of working with them falls short. Raman shares his perspective on how the industry grew, why some biotech clients feel overlooked by large CDMOs, and where smaller providers have an opportunity to compete.
We discuss:
• How pharma outsourcing evolved from transactional manufacturing to strategic partnerships
• What site visits, employee enthusiasm, and company culture reveal about a supplier
• Why customer experience matters from the first RFP through batch delivery
• How biotech funding and post-COVID changes affected CDMO demand
• Differences in capacity across oral solid dose and sterile fill-finish manufacturing
• Risk-sharing, pricing models, and aligned incentives between sponsors and CDMOs
• How GLP-1s and peptides created opportunities for some manufacturers
• AI-driven drug discovery, preclinical research, and the lag before new molecules reach manufacturing
• Why Raman recommends starting AI adoption with business processes
ABOUT RAMAN SEHGAL
Raman Sehgal is the founder of ramarketing and host of the Molecule to Market podcast. He also co-founded Lead Candidate, a talent acquisition business serving the pharmaceutical outsourcing sector. He brings more than two decades of experience working with CDMOs and pharmaceutical service providers.
ABOUT SUBHI SAADEH
Subhi Saadeh is a combination product quality consultant, founder of Combinate, and host of Let’s Combinate. His experience spans pharmaceutical and medical device quality, supplier and contract manufacturer oversight, audits, and quality systems. He helps pharma companies solve device problems and device companies solve pharma problems.
Find Raman on LinkedIn and listen to Molecule to Market. Subscribe to Let’s Combinate for conversations on combination products, drug delivery, pharmaceutical manufacturing, and quality.
Thank you to the CDMO Live Americas team for making this conversation possible.
Getting pharma, medical device, and drug-device combination products into clinical trials takes a clear strategy for INDs, IDEs, FDA meetings, and first-in-human studies.
Dr. Robert Bilkovski joins Subhi Saadeh to discuss clinical development, pre-IND meetings, Q-Submissions, clinical trial design, site selection, and sponsor oversight.
What should you have figured out before meeting with FDA? How does the clinical strategy change when you pair an existing drug with a new delivery device? And what happens between preparing a submission and enrolling the first patient?
IN THIS EPISODE
ABOUT DR. ROBERT BILKOVSKI
Contact Robert: http://www.RNBVenturesConsulting.com/podcast
Dr. Robert Bilkovski is an emergency physician whose industry experience includes Hospira, GE Healthcare, and Abbott Molecular. He advises companies on clinical development as a fractional chief medical officer and is the author of Make Your Story Believable: Diagnosing the Pitfalls of Healthcare Innovation.
ABOUT SUBHI SAADEH
Subhi Saadeh is the founder of Combinate and host of Let’s Combinate, helping pharmaceutical and medical device companies solve the quality challenges where drugs and devices meet. His career spans engineering and quality roles at Baxter, Pfizer, and Gilead, supporting drug delivery systems and combination products from development and clinical use through launch and commercial manufacturing.
His experience includes prefilled syringes, autoinjectors, infusion devices, and a frozen prefilled syringe platform supplying more than 100 million units annually. He has chaired industry working groups through the Combination Products Coalition and Rx-360, contributed to AAMI’s combination product work, and co-created the CQA Master Class. Subhi is an ASQ Certified Quality Auditor and Certified Quality Engineer, an ISO 13485 Lead Auditor, and a bioengineering graduate of the University of Illinois Chicago.
WORK WITH SUBHI
Consulting, audits, and training:https://letscombinate.com/services/
Discuss your project:https://calendly.com/letscombinate/quick-chat
LinkedIn:https://www.linkedin.com/in/subhi-saadeh-1169aa21/
Email: [email protected]
RESOURCES
Free guide: Drug vs. Device Qualityhttps://letscombinate.kit.com/216fbfc6c2
CQA Master Class:https://cqeacademy.teachable.com/p/the-cqa-master-class-course
FOLLOW LET’S COMBINATE
YouTube:https://www.youtube.com/@LetsCombinate
Spotify:https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2
Apple Podcasts:https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792
#ClinicalTrials #CombinationProducts #FDA
What pharma companies want from CDMOs, and how closely that matches what CDMOs think matters. Recorded at CDMO Live Americas with Kaan Kekec, Partner at Simon-Kucher, on the CDMO Growth Report 2026: why quality ranked first for sponsors while CDMOs emphasized speed, how to validate a value proposition, and pricing challenges for drug delivery devices.
Drawing on research conducted with PharmaSource, Kaan explains the gap between sponsor expectations and supplier perceptions. We discuss why quality needs to be demonstrated throughout a partnership, how companies can validate their value proposition, and what drug delivery device suppliers miss when they don't understand the markets their products ultimately serve.
IN THIS EPISODE
- Why quality ranked first for sponsors while CDMOs placed more weight on speed
- Why your value proposition needs to reflect what customers recognize and value
- How customer interviews and competitor comparisons reveal blind spots
- Why large pharma and small biotech need different conversations
- How access to technical experts can influence customer experience and win rates
- Pricing challenges for drug delivery devices across regions and end markets
- Integrated device manufacturing, fill-finish, and assembly
- Why certifications alone don't tell the whole quality story
- How clearer expectations can improve sponsor-CDMO partnerships
ABOUT KAAN KEKEC
Kaan-Fabian Kekec is a Partner at Simon-Kucher with 15 years of consulting experience helping pharma services and drug delivery companies improve their commercial strategy, pricing, and customer value proposition.
Kaan on LinkedIn:
https://www.linkedin.com/in/kaan-fabian-kekec-3b799632/
CDMO Growth Report 2026 (Simon-Kucher, with PharmaSource):
https://www.simon-kucher.com/en/insights/cdmo-growth-report-2026
Thank you to Luke and the CDMO Live team for the opportunity to record this conversation in person.
https://pharmasource.global/events/cdmo-live-americas/
RELATED VIDEOS
Working with a Device CDMO: Common Sponsor Mistakes
https://youtu.be/d2SDwndXuCk
What Is a Quality Agreement? Pharma, Medical Device, and CDMO Responsibilities
https://youtu.be/ocohmInoHkE
Co-Packaged Combination Product Kits: How to Qualify a Finished Device and Its Supplier
https://youtu.be/BEoEr4ljEo4
Need help with CDMO oversight, quality agreements, or supplier audits on a combination product?
https://letscombinate.com/services/
Free guide: Drug vs. Device Quality comparison
https://letscombinate.kit.com/216fbfc6c2
ABOUT SUBHI SAADEH
Subhi Saadeh is the Founder and Principal of Let's Combinate, a consultant, auditor, and trainer specializing in drug-device combination products, medical devices, and pharmaceutical quality systems. He has held quality and engineering roles at Pfizer, Gilead, and Baxter, with a focus on design controls, supplier quality, inspection readiness, and translating regulatory expectations into practical execution.
Subhi is an ISO 13485 Lead Auditor and an ASQ Certified Quality Auditor and Certified Quality Engineer. He has chaired the Combination Product Working Group for Rx-360, served as International Committee Chair for the Combination Products Coalition (CPC) and as a member of ASTM Committee E55, and served on AAMI's Combination Products Committee.
CONNECT WITH SUBHI
Consulting, audits, and training:
https://letscombinate.com/services/
Discuss a project:
https://calendly.com/letscombinate/quick-chat
LinkedIn:
https://www.linkedin.com/in/subhi-saadeh-1169aa21/
Email:
FOLLOW LET'S COMBINATE
YouTube:
https://www.youtube.com/@LetsCombinate
Spotify:
https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2
Apple Podcasts:
https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792
#CDMO #PharmaOutsourcing #CombinationProducts
Career growth in pharma and medical devices takes technical knowledge, leadership, and the ability to earn your team’s trust. In this episode, Subhi Saadeh shares a lesson from leading a drug-device combination product program that changed how he approached his career in quality.
Early in my career, I was excited about getting on big projects, gaining exposure, and proving what I could do. But leading a team with deeper technical expertise than I had taught me something I had to learn the hard way: it’s not about you.
I share how asking questions, following through, and helping people address their problems helped me earn their respect and become a more effective lead.
In this episode:
- Understanding what your team and stakeholders need from you
- Leading technical experts while building your own experience
- Being coachable and following through on what you learn
- Applying customer focus beyond the quality system
- Building credibility by helping others move their work forward
- What a mentor meant by “their cookie, your crumb”
Chapters:
00:00 The career lesson: It’s not about you
00:25 Career exposure and proving yourself
00:53 Why people value having you around
01:17 Customer focus in quality and leadership
02:03 Leading a complex combination product program
03:25 Feeling out of your depth
03:42 Understanding what your team needs
04:02 Being coachable and earning credibility
05:07 Rethinking career growth and success
06:10 “Their cookie, your crumb”
About Subhi:
Subhi Saadeh is a Quality Professional, Founder & Principal of Combinate, and host of Let’s Combinate: Drugs + Devices. With a background in Quality, Manufacturing Operations, and R&D, he has works with medical device and pharmaceutical organizations supporting the development and launch of combination products for vaccines, generics, and biologics.
Subhi served as the International Committee Chair for the Combination Products Coalition (CPC) and was a member of ASTM Committee E55. He previously served on AAMI’s Combination Products Committee. He is an ASQ Certified Quality Auditor (CQA), Certified Quality Engineer (CQE), and ISO 13485 Lead Auditor.
Connect and learn more:
Website: [letscombinate.com](https://letscombinate.com)
LinkedIn: [Subhi Saadeh](https://www.linkedin.com/in/subhi-saadeh-1169aa21/)
Email: [email protected]
CQA Master Class: [Become a Certified Quality Auditor](https://cqeacademy.teachable.com/p/the-cqa-master-class-course)
Watch and listen:
[YouTube](https://www.youtube.com/@LetsCombinate)
[Spotify](https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2)
[Apple Podcasts](https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792)
Subscribe for weekly conversations where drugs and devices meet.
For questions, inquiries, or suggestions, please reach out at letscombinate.com or email [email protected].
Combination product quality with Ben Locwin: why drug and device quality systems differ, how human factors studies are designed, what to do when a CDMO's clean audit doesn't match its performance, and how ISO 14971 risk management compares with ICH Q9.
This conversation was recorded for Ben Locwin's Life Science Shifts podcast from Reliant Life Sciences, with Subhi Saadeh as the guest. It covers where pharma and medical device thinking diverge, and what that means when one product has to satisfy both.
IN THIS EPISODE
- Why drugs and devices prove safety and effectiveness in different ways
- Drug development (clinical, nonclinical, CMC) vs. device design controls
- Why the same syringe can need new human factors work for a different user
- How human factors studies are built: patient and caregiver arms, trained and untrained users
- CGMPs for combination products: QMSR, ISO 13485, ICH, and PIC/S
- Global harmonization: IMDRF for devices, ICH for drugs, and the gap for combination products
- CDMO oversight when the supplier scorecard and the audit result don't match what you see
- ISO 14971 and ISO/TR 24971 vs. ICH Q9: initial and updated probability
- FMEA as a living document
TIMESTAMPS
0:00 Pharma vs. medical device quality: two philosophies
2:10 Drug development vs. device design controls
4:29 Why device trials rarely use placebo controls
9:52 Platform technology and delivery devices
12:10 Same device, different user: bracketing and generic platforms
14:14 Human factors studies: recruitment, study arms, formative studies
15:40 CGMPs for combination products: QMSR, ISO 13485, ICH, PIC/S
16:58 Harmonization: IMDRF and ICH
19:12 Conway's Law and organizational inertia
22:06 Staying objective as a consultant
25:10 CDMO oversight: when the scorecard doesn't match reality
30:18 Scoring bias in subjective weighting
31:14 ISO 14971 vs. ICH Q9 risk management
32:32 FMEA as a living document
RELATED VIDEOS
Pharma vs. Medical Device Quality Systems: 5 Differences
https://youtu.be/xG0htEu0ph4
Working with a Device CDMO: Common Sponsor Mistakes
https://youtu.be/d2SDwndXuCk
ICH Q9 Explained
https://youtu.be/Is67hbh71RY
Design Controls Explained for Pharma and Combination Product Teams
https://youtu.be/f7esiLpUhfM
Need help with CDMO oversight, supplier audits, or risk management on a combination product?
https://letscombinate.com/services/
ABOUT BEN LOCWIN
Ben Locwin is Vice President at Reliant Life Sciences and host of the Life Science Shifts podcast. His work spans drug therapies, vaccines, and medical devices, and he is a frequent industry speaker and commentator on pharma and medical device quality.
Reliant Life Sciences:
https://www.reliantlifesciences.com/
ABOUT SUBHI SAADEH
Subhi Saadeh is the Founder and Principal of Let's Combinate, a consultant, auditor, and trainer specializing in drug-device combination products, medical devices, and pharmaceutical quality systems. He has held quality and engineering roles at Pfizer, Gilead, and Baxter, with experience spanning quality, R&D, and commercialization and a focus on design controls, supplier quality, inspection readiness, and translating regulatory expectations into practical execution.
Subhi is an ISO 13485 Lead Auditor and an ASQ Certified Quality Auditor and Certified Quality Engineer. He has chaired the Combination Product Working Group for Rx-360, served as International Committee Chair for the Combination Products Coalition (CPC) and as a member of ASTM Committee E55, and served on AAMI's Combination Products Committee.
CONNECT WITH SUBHI
Consulting, audits, and training:
https://letscombinate.com/services/
Discuss a project:
https://calendly.com/letscombinate/quick-chat
LinkedIn:
https://www.linkedin.com/in/subhi-saadeh-1169aa21/
Email:
FOLLOW LET'S COMBINATE
YouTube:
https://www.youtube.com/@LetsCombinate
Spotify:
https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2
#CombinationProducts #HumanFactors #RiskManagement
21 CFR Part 4 sets the CGMP requirements for combination products. If your product has a drug and a device in it, you're on the hook for both sets of regulations. In this video, I walk through Part 4 Subpart A section by section: the scope, the key definitions, which CGMPs apply, and the two ways to comply, including the streamlined approach under 4.4(b).
Updated for February 2026, when the device side moved to the QMSR and ISO 13485, plus the new medical gas provisions.
Working on your first combination product program? Watch this next: https://youtu.be/uG_Ea__-Pjc
Want a second set of eyes on your combination product quality system? Book a quick call: https://calendly.com/letscombinate/quick-chat
Sources
21 CFR Part 4 (eCFR): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-4
FDA Guidance, CGMP Requirements for Combination Products: https://www.fda.gov/media/90425/download
Chapters
0:00 Intro
0:50 21 CFR Part 4 Subpart A vs. Subpart B
2:00 Full compliance vs. the streamlined approach
2:39 21 CFR 4.1: Scope (single-entity and co-packaged)
3:52 21 CFR 4.2 and 4.3: Definitions and which CGMPs apply
4:37 21 CFR 4.4: How to comply with CGMPs for combination products
5:38 Drug-based system: ISO 13485 and QMSR provisions to add
7:58 Device-based system: 21 CFR 211 provisions to add
11:24 Medical gas and 4.4(c)–(e): separate facilities
12:10 Wrap-up
About me
I'm Subhi Saadeh. I help companies make drug and device quality systems work together. I'm a consultant, auditor, and trainer focused on combination products, an ISO 13485 Lead Auditor, and an ASQ CQA and CQE. I've worked on prefilled syringes, autoinjectors, IV bags, cartridges, and vial-based systems, from clinical through commercial.
🌐 https://letscombinate.com
📅 https://calendly.com/letscombinate/quick-chat
💼 https://www.linkedin.com/in/subhi-saadeh-1169aa21
#CombinationProducts #21CFRPart4 #QMSR
QMSR became effective on February 2, 2026. Alongside that change, FDA retired the Quality System Inspection Technique (QSIT) and began using the inspection process described in Compliance Program 7382.850.
What does that mean for industry and how should we use the new program to prepare?
In this episode of Let’s Combinate: Drugs + Devices, Subhi Saadeh introduces a four-part series on QMSR inspection readiness. We compare QSIT’s four major inspection subsystems with the new program’s six QMS areas, explore how risk informs inspection coverage, and identify where industry should start reading.
The episode also features an excerpt from Subhi’s conversation with Eric Pittman, a former FDA investigator who spent a decade as editor-in-chief of FDA’s Investigations Operations Manual.
IN THIS EPISODE
• What replaced QSIT and where to find it
• Why Part III is a useful starting point for industry
• How FDA reorganized inspection coverage into six QMS areas
• How product risks and risk management documentation help guide record selection
• What’s coming in the QMSR inspection readiness series
TIMESTAMPS
00:00 QSIT is gone: What changed with QMSR
00:50 The new FDA inspection program
01:39 The four-part inspection readiness series
02:47 Eric Pittman: Where industry should start
04:14 Will FDA publish a new QSIT guide?
05:06 Comparing the old and new inspection approaches
05:47 Four major subsystems to six QMS areas
06:57 Inspection models and record selection
07:37 Risk, controls, and inspection evidence
08:08 What’s next in the series
THE SERIES
1. QSIT to QMSR: Understanding the new inspection program
2. Inspection models, coverage, and record selection
3. The six QMS areas and how they connect
4. Inspection readiness: Preparing people, processes, and records, with lessons from early QMSR warning letters
RESOURCES
FDA Compliance Program 7382.850 — Inspection of Medical Device Manufacturers
Part III begins on page 20. Attachment A details the QMS areas, elements, and requirements.
https://www.fda.gov/media/80195/download
FDA Investigations Operations Manual — Chapter 5
https://www.fda.gov/media/166533/download
FDA QMSR Frequently Asked Questions
https://www.fda.gov/medical-devices/quality-management-system-regulation-qmsr/quality-management-system-regulation-frequently-asked-questions
ABOUT SUBHI SAADEH
Subhi Saadeh is the Founder and Principal of Let’s Combinate, a consultant, auditor, and trainer specializing in drug-device combination products, medical devices, and pharmaceutical quality systems. His experience spans quality, R&D, and commercialization, with a focus on design controls, supplier quality, inspection readiness, and translating regulatory expectations into practical execution.
Subhi is an ISO 13485 Lead Auditor and an ASQ Certified Quality Auditor and Certified Quality Engineer.
CONNECT WITH SUBHI
Consulting, audits, and training:
https://letscombinate.com
LinkedIn:
https://www.linkedin.com/in/subhi-saadeh-1169aa21/
Schedule a quick chat:
https://calendly.com/letscombinate/quick-chat
Email:
FOLLOW LET’S COMBINATE
YouTube:
https://www.youtube.com/@LetsCombinate
Spotify:
https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2
Apple Podcasts:
https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792
A huge part of the job is knowing how to interview people, understand how work is actually performed, and corroborate what you hear against records, observations, and other objective evidence.In this episode, I pulled one of the lessons from the auditing course Andy Robertson and I developed and walk through some of the fundamentals of audit interviewing: building rapport, asking open-ended questions, avoiding overly checklist-driven interviews, corroborating information, managing group interviews and translators, and handling some of the situations that make interviews difficult.If documents and records alone were enough to understand the quality of an organization, every audit could be a desktop audit. People are a huge part of what makes an audit work.Full CQA Master Class:https://cqeacademy.teachable.com/p/the-cqa-master-class-courseChapters0:00 Intro1:39 Interviewing Fundamentals3:04 Conversational vs. Checklist3:49 Building Rapport4:29 Focus on the Process5:30 Open-Ended Questions5:58 Corroborating Information6:44 Group Interviews7:29 Using Translators8:20 Interview Challenges10:29 Time Management11:16 ClosingAbout SubhiSubhi Saadeh is the Founder and Principal of Let’s Combinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, and regulatory expectations across drug and device domains. He is a consultant, auditor, trainer, and speaker with experience across pharma, biotech, medical devices, and combination products.Learn more about Let’s Combinate:https://letscombinate.com/Connect with Subhi on LinkedIn:https://www.linkedin.com/in/subhi-saadeh-1169aa21Need help?https://calendly.com/letscombinate/let-s-combinate-intro-session#Quality #Auditing #QualityAssurance #CQA #Pharma #MedicalDevices #CombinationProducts
Quality has a reputation for saying no.
Sometimes that’s exactly the right call. Other times, “no” is just the easiest answer.
In this episode, Subhi breaks down four situations where Quality should absolutely stop the train, and a few where it’s worth stepping back and asking what’s really driving the no in the first place.
Subhi covers:
when there is real patient or product risk
when the evidence doesn’t support the decision
when moving forward would clearly violate requirements or SOPs
when schedule or business pressure is pushing a team to close something that isn’t actually closed
He also talks through some weaker reasons Quality says no, including:
personal preference or “this is how we’ve always done it”
uncertainty from lack of technical familiarity
applying more GMP rigor than the stage of development actually requires
If you work in quality, combination products, development, manufacturing, or technical leadership, this is a practical look at how to think about “no” in a more risk-based way.
Timestamps
00:00 Why Quality Says No
00:45 Channel Intro and Setup
02:02 No When Risk Is Real
03:06 No When Evidence Fails
05:02 No When Requirements Break
05:44 No to Schedule Pressure
07:48 Bad No From Preference
08:33 Bad No From Uncertainty
09:20 Overkill and Phase GMPs
10:08 Build Flexible Quality Culture
12:16 Wrap Up and Takeaways
Subhi Saadeh is a consultant, trainer, auditor, and the Founder and Principal of Let’s Combinate. He has spent his career across medical devices and pharmaceuticals, with experience spanning research and development, industrialization, quality systems, and combination products. Through Let’s Combinate, he helps professionals and organizations better understand and navigate the intersection of drugs, devices, quality, and regulatory requirements.
Connect with Subhi Saadeh
LinkedIn: https://www.linkedin.com/in/subhi-saadeh-1169aa21/
Website: http://letscombinate.com/
Book a quick chat: https://calendly.com/letscombinate/quick-chat
Email: [email protected]
Listen / Follow Let’s Combinate
YouTube: https://www.youtube.com/@LetsCombinate
Spotify: https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2
Apple Podcasts: https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792
#Quality #CombinationProducts #Pharma #MedTech #RiskManagement #GMP #DesignControls #SupplierQuality #QualitySystems #LetsCombinate
From the publisher's feed

30,802 Listeners

1,291 Listeners

112,262 Listeners

61,518 Listeners

0 Listeners